{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2023"],"data_sharing_plan":["IPD Sharing (as of January 2023): Undecided"],"condition":["Peritoneal Neoplasms","Carcinoma","Colorectal cancer","Colorectal Neoplasms","Colorectal Cancer Metastatic","Peritoneal Carcinomatosis"],"disease":["Peritoneal Neoplasms","Carcinoma","Colorectal Cancer","Colorectal Neoplasms","Colorectal Cancer Metastatic","Peritoneal Carcinomatosis"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/6231"],"location":["Netherlands"],"study_start_month":["4"],"keyword":["Peritonitis carcinomatosa","Capecitabine","Metastatic colorectal cancer"],"repository":["ECRIN MDR"],"study_status":["Not yet recruiting"],"additional_accession":[]},"is_claimable":false,"name":"Galunisertib Combined With Capecitabine in Advanced CRC With PM","description":"This is a two-center open-label non-randomized proof of principle study consisting of a dose-finding part (phase I) and phase II study with Simon two-stage design investigating the anti-tumor activity of the combination of capecitabine and galunisertib in patients with colorectal cancer with peritoneal metastases.","dates":{"creation":"2023-04-15"},"accession":"6231","cross_references":{"ClinicalTrials___gov":["NCT05700656"]}}